I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Jonathan Fox Biography and Net Worth

Director of Edgewise Therapeutics

Jonathan C. Fox, M.D., Ph.D., FACC, serves as a member of our board of directors and is the president and chief medical officer for cardiovascular and renal diseases at BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to that, Dr. Fox served as the chief medical officer of MyoKardia, Inc. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, and held various senior R&D positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca. He was also on the faculty of the University of Pennsylvania School of Medicine. Dr. Fox serves on the board at ML BioSolutions and is a trustee of the Lankenau Institute for Medical Research. He is currently an adjunct Professor of Medicine at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology.

What is Jonathan C. Fox's net worth?: The estimated net worth of Jonathan C. Fox is at least $369,138.00 as of December 26th, 2023. Dr. Fox owns 10,857 shares of Edgewise Therapeutics stock worth more than $369,138 as of November 2nd. This net worth estimate does not reflect any other assets that Dr. Fox may own. Learn More about Jonathan C. Fox's net worth.
How do I contact Jonathan C. Fox?: The corporate mailing address for Dr. Fox and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on Jonathan C. Fox's contact information.
Has Jonathan C. Fox been buying or selling shares of Edgewise Therapeutics?: Jonathan C. Fox has not been actively trading shares of Edgewise Therapeutics within the last three months. Most recently, on Tuesday, December 26th, Jonathan C. Fox bought 10,857 shares of Edgewise Therapeutics stock. The stock was acquired at an average cost of $9.30 per share, with a total value of $100,970.10. Following the completion of the transaction, the director now directly owns 10,857 shares of the company's stock, valued at $100,970.10. Learn More on Jonathan C. Fox's trading history.
Who are Edgewise Therapeutics' active insiders?: Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.
Are insiders buying or selling shares of Edgewise Therapeutics?: During the last twelve months, Edgewise Therapeutics insiders bought shares 2 times. They purchased a total of 465,402 shares worth more than $5,100,965.10. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 592,545 shares worth more than $11,865,014.27. The most recent insider tranaction occured on September, 23rd when General Counsel John R Moore sold 20,922 shares worth more than $578,074.86. Insiders at Edgewise Therapeutics own 24.1% of the company. Learn More about insider trades at Edgewise Therapeutics.
Information on this page was last updated on 9/23/2024.

Jonathan C. Fox Insider Trading History at Edgewise Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/26/2023	Buy	10,857	$9.30	$100,970.10	10,857

Jonathan C. Fox Buying and Selling Activity at Edgewise Therapeutics

Edgewise Therapeutics Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Today's Range

Now: $34.00

$33.48

$34.12

50 Day Range

MA: $26.29

$16.85

$35.57

2 Week Range

Now: $34.00

$5.12

$36.66

Volume

445,358 shs

Average Volume

958,294 shs

Market Capitalization

$3.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2

True paradigm shift

From Porter & Company | Ad